Iovance Biotherapeutics (IOVA) had the highest return last quarter by a mid-cap US stock, returning 256.3%.

ASSET	QUARTER	% RETURN
Iovance Biotherapeutics (IOVA)	Q3 2026	256.25%
Strive (ASST)	Q3 2026	171.31%
Kodiak Sciences (KOD)	Q3 2026	146.23%
CareDx (CDNA)	Q3 2026	126.4%
GRAIL, LLC (GRAL)	Q3 2026	106.48%
AtriCure (ATRC)	Q3 2026	98.8%
Abcellera Biologics (ABCL)	Q3 2026	89.73%
Schrodinger (SDGR)	Q3 2026	89.1%
CVR Energy (CVI)	Q3 2026	88%
Ringcentral (RNG)	Q3 2026	86.52%
Pulse Biosciences (PLSE)	Q3 2026	79.76%
NIQ Global Intelligence (NIQ)	Q3 2026	79.43%
Okeanis Eco Tankers (ECO)	Q3 2026	78.02%
Huron Consulting (HURN)	Q3 2026	69.82%
Heartflow, Inc Common Stock (HTFL)	Q3 2026	69.51%
Caris Life Sciences, Inc Common Stock (CAI)	Q3 2026	69.32%
PBF Energy (PBF)	Q3 2026	68.14%
CBIZ (CBZ)	Q3 2026	66.53%
Accelerant (ARX)	Q3 2026	65.66%
GigaCloud Technology Inc Class A Ordinary Shares (GCT)	Q3 2026	63.54%
Amylyx Pharmaceuticals (AMLX)	Q3 2026	63.12%
ManpowerGroup (MAN)	Q3 2026	62.66%
Dorian LPG (LPG)	Q3 2026	61.14%
Ionic Digital Inc Class A Common Stock (IOND)	Q3 2026	60.66%
Torm PLC Class A (TRMD)	Q3 2026	59.86%

Mid-cap stocks are treated as having a market cap between $2B and $10B.